134 related articles for article (PubMed ID: 11794005)
1. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment.
Durnin C; Hind ID; Ghani SP; Yates DB; Molz KH
Proc West Pharmacol Soc; 2001; 44():83-4. PubMed ID: 11794005
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment.
Durnin C; Hind ID; Wickens MM; Yates DB; Molz KH
Proc West Pharmacol Soc; 2001; 44():81-2. PubMed ID: 11794004
[No Abstract] [Full Text] [Related]
3. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in young and elderly subjects.
Durnin C; Hind ID; Ghani SP; Yates DB; Cross M
Proc West Pharmacol Soc; 2001; 44():79-80. PubMed ID: 11794003
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in male and female subjects.
Durnin C; Hind ID; Ghani SP; Yates DB; Gegg J
Proc West Pharmacol Soc; 2001; 44():77-8. PubMed ID: 11794002
[No Abstract] [Full Text] [Related]
5. Effect of food on the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR).
Durnin C; Hind ID; Channon E; Yates DB; Cross M
Proc West Pharmacol Soc; 2001; 44():75-6. PubMed ID: 11794001
[No Abstract] [Full Text] [Related]
6. Dose proportionality of the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR).
Durnin C; Hind ID; Ghani SP; Yates DB; Cross M
Proc West Pharmacol Soc; 2001; 44():73-4. PubMed ID: 11794000
[No Abstract] [Full Text] [Related]
7. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules.
Vashi V; Harris S; El-Tahtawy A; Wu D; Cipriano A
J Clin Pharmacol; 2005 May; 45(5):547-54. PubMed ID: 15831778
[TBL] [Abstract][Full Text] [Related]
8. Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist.
Toyama K; Uchida N; Ishizuka H; Sambe T; Kobayashi S
J Clin Pharmacol; 2015 Sep; 55(9):975-84. PubMed ID: 25807927
[TBL] [Abstract][Full Text] [Related]
9. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients.
Davison SN; Mayo PR
J Opioid Manag; 2008; 4(6):335-6, 339-44. PubMed ID: 19192761
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.
Sathyan G; Xu E; Thipphawong J; Gupta SK
BMC Clin Pharmacol; 2007 Feb; 7():2. PubMed ID: 17270055
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs.
Smith LJ; KuKanich B; Hogan BK; Brown C; Heath TD; Krugner-Higby LA
J Vet Pharmacol Ther; 2008 Oct; 31(5):415-22. PubMed ID: 19000260
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs.
Guedes AG; Papich MG; Rude EP; Rider MA
J Vet Pharmacol Ther; 2008 Aug; 31(4):334-43. PubMed ID: 18638294
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius).
Guzman DS; KuKanich B; Drazenovich TL; Olsen GH; Paul-Murphy JR
Am J Vet Res; 2014 Jun; 75(6):527-31. PubMed ID: 24866507
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ
J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
[TBL] [Abstract][Full Text] [Related]
16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
17. Opioid conversion guidelines for managing adult cancer pain.
Derby SA
Am J Nurs; 1999 Oct; 99(10):62-5. PubMed ID: 10542852
[No Abstract] [Full Text] [Related]
18. Correlates of nonmedical use of hydromorphone and hydrocodone:results from a national household survey.
Smith MY; Haddox JD; Di Marino ME
J Pain Palliat Care Pharmacother; 2007; 21(3):5-17. PubMed ID: 18032351
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of hydromorphone hydrochloride in healthy dogs.
KuKanich B; Hogan BK; Krugner-Higby LA; Smith LJ
Vet Anaesth Analg; 2008 May; 35(3):256-64. PubMed ID: 18282253
[TBL] [Abstract][Full Text] [Related]
20. Controlled-release opioids and alcohol.
Darke AC
CMAJ; 2006 Jan; 174(3):352. PubMed ID: 16446485
[No Abstract] [Full Text] [Related]
[Next] [New Search]
